Alcon Research, Ltd.

Novartis Ag

Merlion Pharmaceuticals Pte. Ltd.

Malay Ghosh

Masood A Chowhan

Laman L Alani

Daniel A Gamache

Bahram Asgharian

Bhagwati P Kabra

Liladhar Murlidhar Waykole

Onkar N Singh

Tingying Zhu

Zaixing Li

Dietmar Flubacher

Jens Sören Worthmann

Christopher Michael Adams

Wesley Wehsin Han

Stephanie Kay Dodd

L Wayne Schneider

Christoph Bucher

Cale Ry McAlister

Johannes Franz Kluge

Jeremiah Douglas Foutch

Francisco Javier Galán

Stephen Hedrick Poor

Nuria Carreras Perdiguer

Brent G Boudreaux

Mark J Bridle

Bryan H Huynh

Adrian Sauceda

Núria Carreras Perdiguer

Wesley Weshin Han

Núria Perdiguer

Onkar Singh

Francisco Javier GALÁN

Francisco Javier Galan

Nuria Perdiguer

The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same

The present invention is directed to the provision of a multi-dose topical ophthalmic composition containing a 1H-indole-1-carboxamide and use thereof for treatment of ophthalmic disease. More specifically the present invention is directed to a multi-dose aqueous ophthalmic composition (e.g., a solution, a suspension, an emulsion or the like) containing a 1H-indole-1-carboxamide (e.g., N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide) and use thereof for treatment of an ophthalmic disease at the back of the eye such as age related macular degeneration (AMD).

Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease

The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.

Carboxylvinyl polymer-containing nanoparticle suspensions

The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.

High concentration olopatadine ophthalmic composition

The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a suspension composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin free base or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.

Finafloxacin suspension compositions

Carboxyvinyl polymer-containing nanoparticle suspensions

The present invention relates to development of efficacious pharmaceutical implant compositions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000.

Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye

Growing community of inventors

Fort Worth, TX, United States of America

Malay Ghosh